Appili Therapeutics Inc. is a Canadian biopharmaceutical company focused on developing innovative treatments for infectious diseases. The company shows strengths in gross margin at 100%, indicating potential for profitability if revenues materialize. However, significant concerns arise from its negative EBITDA and net margins, alongside a very low current and quick ratio, suggesting severe liquidity issues. The drastic 50% drop in stock price today reflects market skepticism, despite high margins, which raises questions about the sustainability of its business model.
Loading financial metrics...
Company has $139K in cash but burned $339K last quarter. At this burn rate, only 0.4 quarters of runway remain without additional financing.
Company posted a loss of $-4.7M over the last year, representing 1236.1% of revenue.
Debt of $13.3M is 96.1x the company's cash position of $139K.
Operating cash flow has been negative for 3 consecutive quarters, burning $1.4M over the last year.
Exceptional revenue growth of 277.1% YoY demonstrates strong market demand and competitive positioning.
Gross margin expanded by 6.5 percentage points, indicating improved pricing power or cost efficiency.
Exceptional gross margin of 98.8% indicates strong pricing power and competitive moat.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Biotechnology companies of a similar size
Based on 2027-Q1 (June 30, 2026)